Cargando…
Immunogenicity of Del19 EGFR mutations in Chinese patients affected by lung adenocarcinoma
BACKGROUND: Mutant peptides presented by cancer cells are superior vaccine candidates than self peptides. The efficacy of mutant K-Ras, P53 and EGFR (Epidermal Growth Factor Receptor) peptides have been tested as cancer vaccines in pancreatic, colorectal, and lung cancers. The immunogenicity of EGFR...
Autores principales: | Pan, Deng, Zhou, Dapeng, Cai, Weijing, Wu, Weibo, Tan, Wen Ling, Zhou, Caicun, Lou, Yanyan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854806/ https://www.ncbi.nlm.nih.gov/pubmed/31722672 http://dx.doi.org/10.1186/s12865-019-0320-1 |
Ejemplares similares
-
MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design
por: Cai, Weijing, et al.
Publicado: (2018) -
Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China
por: Li, Xuefei, et al.
Publicado: (2016) -
Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer
por: Pan, Hui, et al.
Publicado: (2016) -
Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases
por: Jiang, Tao, et al.
Publicado: (2020) -
Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients
por: Zhao, Chao, et al.
Publicado: (2020)